Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects
Conditions: Spinal Cord Injuries; Chronic Spinal Cord Injury; Subacute Spinal Cord Injury Intervention: Drug: NVG-291 Sponsor: NervGen Pharma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials